Top

International Journal of Colorectal Disease

Published in:

01-02-2020 | Regorafenib | Original Article

Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?

Authors: Qi Zhang, Qianqian Wang, Xicheng Wang, Jian Li, Lin Shen, Zhi Peng

Published in: International Journal of Colorectal Disease | Issue 2/2020

Abstract

Purpose

Direct randomized comparisons of regorafenib, TAS-102, and fruquintinib for treating metastatic colorectal cancer (mCRC) are lacking. Here, we evaluated the efficacy and safety of three agents by a systematic review and a network meta-analysis.

Methods

We included phase III randomized controlled trials in the PubMed, Embase, and Scopus Cochrane databases and ClinicalTrials.gov registry from initiation until January 2019. Data from randomized controlled trials including overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were extracted. Direct meta-analysis and indirect meta-analysis using network meta-analysis were assessed.

Results

Five trials comprising a total of 2586 patients were included. For efficacy analysis of OS, no statistically significant differences were observed between regorafenib and TAS-102 (HR 0.945, 95% CI [0.677, 1.320], P = 0.753), regorafenib and fruquintinib (HR 1.056, 95% CI [0.690, 1.621], P = 0.814), or TAS-102 and fruquintinib (HR 1.117, 95% CI [0.740, 1.685], P = 0.610). However, fruquintinib was superior in PFS compared with TAS-102 (HR 1.756, 95% CI [1.079, 2.857], P = 0.023). Regorafenib and TAS-102 appeared to have a similar effect on PFS (HR 0.907, 95% CI [0.611, 1.346], P = 0.641), as did regorafenib and fruquintinib (HR 1.592, 95% CI [0.968, 2.618], P = 0.067). None of the three agents were better in terms of all grade AEs or any grade of 3–5 AEs. However, subgroup analysis of AEs exhibited different toxicity profiles between the three drugs.

Conclusions

Indirect comparison suggested that the three agents had similar OS but that fruquintinib was superior in terms of PFS compared with that of TAS-102. These three agents had different toxicity profiles.

Van Cutsem E, Nordlinger B, Cervantes A (2010) Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 21(Suppl 5):v93–v97. https://doi.org/10.1093/annonc/mdq222 CrossRefPubMed

Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371(17):1609–1618. https://doi.org/10.1056/NEJMoa1403108 CrossRefPubMed

Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408–1417. https://doi.org/10.1056/NEJMoa0805019 CrossRefPubMed

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Tian Y, Xu F, Sidhu R (2014) Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25(7):1346–1355. https://doi.org/10.1093/annonc/mdu141 CrossRefPubMed

Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30(28):3499–3506. https://doi.org/10.1200/jco.2012.42.8201 CrossRefPubMed

Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, Thierauch KH, Zopf D (2011) Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129(1):245–255. https://doi.org/10.1002/ijc.25864 CrossRefPubMed

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz H-J, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D, Group CS (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomized, placebo-controlled, phase 3 trial. Lancet (London, England) 381(9863):303–312. https://doi.org/10.1016/S0140-6736(12)61900-X CrossRef

Li J, Qin S, Xu R, Yau TCC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J, Kim TW (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16(6):619–629. https://doi.org/10.1016/S1470-2045(15)70156-7 CrossRefPubMed

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D’Hoore A, Diaz-Rubio E, Douillard J-Y, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne C-H, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJG, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386–1422. https://doi.org/10.1093/annonc/mdw235 CrossRefPubMed

10.

Benson AB, Venook AP, Cederquist L, Chan E, Chen Y-J, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wu CS, Gregory KM, Freedman-Cass D (2017) Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in. Oncology. 15(3):370. https://doi.org/10.6004/jnccn.2017.0036 CrossRef

11.

Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909–1919. https://doi.org/10.1056/NEJMoa1414325 CrossRefPubMed

12.

Xu J, Kim TW, Shen L, Sriuranpong V, Pan H, Xu R, Guo W, Han S-W, Liu T, Park YS, Shi C, Bai Y, Bi F, Ahn JB, Qin S, Li Q, Wu C, Ma D, Lin D, Li J (2018) Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. J Clin Oncol 36(4):350–358. https://doi.org/10.1200/JCO.2017.74.3245 CrossRefPubMed

13.

Bekaii-Saab T, Kim R, Kim TW, O’Connor JM, Strickler JH, Malka D, Sartore-Bianchi A, Bi F, Yamaguchi K, Yoshino T, Prager GW (2019) Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. Clin Colorectal Cancer 18(1):e117–e129. https://doi.org/10.1016/j.clcc.2018.11.002 CrossRefPubMed

14.

Cao J, Zhang J, Peng W, Chen Z, Fan S, Su W, Li K, Li J (2016) A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, −2, and − 3 tyrosine kinases in Chinese patients with advanced solid tumors. Cancer Chemother Pharmacol 78(2):259–269. https://doi.org/10.1007/s00280-016-3069-8 CrossRefPubMed

15.

Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1027. https://doi.org/10.1200/jco.2005.06.081 CrossRefPubMed

16.

Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H, Pan H, Guo W, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, Wu C, Cheng Y, Chen D, Li W, Sun S, Yu Z, Cao P, Chen H, Wang J, Wang S, Wang H, Fan S, Hua Y, Su W (2018) Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. Jama 319(24):2486–2496. https://doi.org/10.1001/jama.2018.7855 CrossRefPubMedPubMedCentral

17.

Shirley M (2018) Fruquintinib: First Global Approval. Drugs 78(16):1757–1761. https://doi.org/10.1007/s40265-018-0998-z CrossRefPubMed

18.

Sueda T, Sakai D, Kudo T, Sugiura T, Takahashi H, Haraguchi N, Nishimura J, Hata T, Hayashi T, Mizushima T, Doki Y, Mori M, Satoh T (2016) Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies. Anticancer Res 36(8):4299–4306PubMed

19.

Masuishi T, Taniguchi H, Hamauchi S, Komori A, Kito Y, Narita Y, Tsushima T, Ishihara M, Todaka A, Tanaka T, Yokota T, Kadowaki S, Machida N, Ura T, Fukutomi A, Ando M, Onozawa Y, Tajika M, Yasui H, Muro K, Mori K, Yamazaki K (2017) Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison. Clin Colorectal Cancer 16(2):e15–e22. https://doi.org/10.1016/j.clcc.2016.07.019 CrossRefPubMed

20.

Neupane B, Richer D, Bonner AJ, Kibret T, Beyene J (2014) Network meta-analysis using R: a review of currently available automated packages. PLoS One 9(12):e115065. https://doi.org/10.1371/journal.pone.0115065 CrossRefPubMedPubMedCentral

21.

Salanti G, Higgins JP, Ades AE, Ioannidis JP (2008) Evaluation of networks of randomized trials. Stat Methods Med Res 17(3):279–301. https://doi.org/10.1177/0962280207080643 CrossRefPubMed

22.

The Cochrane Collaboration (2014) Version 5.1Review Manager (RevMan) [Computer program]. The Nordic Cochrane Centre, Copenhagen

23.

Abrahao ABK, Ko YJ, Berry S, Chan KKW (2018) A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis. Clin Colorectal Cancer 17(2):113–120. https://doi.org/10.1016/j.clcc.2017.10.016 CrossRefPubMed

24.

Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama C, Denda T, Satake H, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Sugiyama M, Komatsu Y, Okuyama H, Baba E, Sakai D, Watanabe T, Tamura T, Yamashita K, Gosho M, Shimada Y (2018) Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. Oncologist 23(1):7–15. https://doi.org/10.1634/theoncologist.2017-0275 CrossRefPubMed

25.

Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T, Grothey A, Van Cutsem E, Wagner A, Cihon F et al (2015) Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Investig New Drugs 33(3):740–750. https://doi.org/10.1007/s10637-014-0154-x CrossRef

26.

Hirano G, Makiyama A, Makiyama C, Esaki T, Oda H, Uchino K, Komoda M, Tanaka R, Matsushita Y, Mitsugi K, Shibata Y, Kumagai H, Arita S, Ariyama H, Kusaba H, Akashi K, Baba E (2015) Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan. Anticancer Res 35(1):371–377PubMed

27.

Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, Dourthe L-M, Etienne P-L, Mineur L, Clisant S, Phelip J-M, Kramar A, Andre T (2016) Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer 16:412. https://doi.org/10.1186/s12885-016-2440-9 CrossRefPubMedPubMedCentral

28.

Bekaii-Saab TS, Ou F-S, Anderson DM, Ahn DH, Boland PM, Ciombor KK, Jacobs NL, Desnoyers RJ, Cleary JM, Meyers JP, Chiorean EG, Pedersen K, Barzi A, Sloan J, McCune JS, Lacouture ME, Lenz HJ, Grothey A (2018) Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)-An ACCRU Network study. J Clin Oncol 36(4_suppl):611. https://doi.org/10.1200/JCO.2018.36.4_suppl.611 CrossRef

29.

Kudo T, Kato T, Kagawa Y, Sakai D, Satoh T, Doki Y, Mori M (2018) Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemotherapy. J Clin Oncol 36(4_suppl):821–821. https://doi.org/10.1200/JCO.2018.36.4_suppl.821 CrossRef

30.

Garcia-Carbonero R, Van Cutsem E, Ciardiello F, Ychou M, Seitz JF, Hofheinz RD, Arriaga Y, Verma U, Grothey A, Miriyala A et al (2016) Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m). Ann Oncol 27. https://doi.org/10.1093/annonc/mdw370.54 CrossRef

31.

Schulz H, Janssen J, Strauss UP, Langen M, Dworschak KU, Fiala-Buskies S, Bokemeyer C (2018) Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Final results of the prospective multicentre non-interventional RECORA study. J Clin Oncol 36(4). https://doi.org/10.1200/JCO.2018.36.4-suppl.748

32.

Fukuoka S, Moriwaki T, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Katsumata K, Ishikawa T, Kashiwada T, Oki E, Yuki S, Gosho M, Shimada Y (2017) Regorafenib (REG) versus trifluridine/tipiracil (TAS-102) as salvage-line in patients with metastatic colorectal cancer refractory to standard chemotherapies (REGOTAS): A propensity score analysis from a JSCCR multicenter observational study. J Clin Oncol 35(15):3540. https://doi.org/10.1200/JCO.2017.35.15_suppl.3540 CrossRef

33.

Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, Dourthe LM, Etienne PL, Mineur L, Clisant S, Phelip JM, Kramar A, Andre T (2016) Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer 16(1):518. https://doi.org/10.1186/s12885-016-2559-8 CrossRefPubMedPubMedCentral

34.

Bertocchi P, Aroldi F, Prochilo T, Meriggi F, Beretta GD, Zaniboni A (2017) Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope? J Chemother (Florence, Italy) 29(2):102–105. https://doi.org/10.1080/1120009x.2016.1247205 CrossRef

35.

Avallone A, Piccirillo MC, Aloj L, Nasti G, Delrio P, Izzo F, Di Gennaro E, Tatangelo F, Granata V, Cavalcanti E, Maiolino P, Bianco F, Aprea P, De Bellis M, Pecori B, Rosati G, Carlomagno C, Bertolini A, Gallo C, Romano C, Leone A, Caracò C, de Lutio di Castelguidone E, Daniele G, Catalano O, Botti G, Petrillo A, Romano GM, Iaffaioli VR, Lastoria S, Perrone F, Budillon A (2016) A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme). BMC Cancer 16:69. https://doi.org/10.1186/s12885-016-2102-y CrossRefPubMedPubMedCentral

36.

Unseld M, Drimmel M, Siebenhuner A, Gleiss A, Bianconi D, Kieler M, Scheithauer W, Winder T, Prager GW (2018) Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib. Clin Colorectal Cancer 17(4):274–279. https://doi.org/10.1016/j.clcc.2018.05.012 CrossRefPubMed

Title: Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Authors: Qi Zhang
Qianqian Wang
Xicheng Wang
Jian Li
Lin Shen
Zhi Peng
Publication date: 01-02-2020
Publisher: Springer Berlin Heidelberg
Keywords: Regorafenib
Colorectal Cancer
Colorectal Cancer
Published in: International Journal of Colorectal Disease / Issue 2/2020
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-019-03477-x

At a glance: The STEP trials

Springer Medicine

Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2020

Comparison of different modalities for the diagnosis of parastomal hernia: a systematic review

Intestinal adenosquamous carcinoma with a synchronous skin metastasis: a immunohistochemical and molecular analysis

Retrospective study on melanosis coli as risk factor of colorectal neoplasm: a 3-year colonoscopic finding in Zhuhai Hospital, China

A multicentre development and validation study of a novel lower gastrointestinal bleeding score—The Birmingham Score

Incidence and prognosis of pulmonary metastasis in colorectal cancer: a population-based study

Delayed septic radiation-induced calcinosis cutis long after cured anorectal cancer